Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

FSD Pharma Inc. (C:HUGE)

Business Focus: Alternative Medicine

INK Edge Outlook

Mostly sunny as of January 01, 2022
For the latest outlook, get the company report

Insider Chart - Past 6 Months

INK Ultra Money Free

Insider Filings

Latest 10 SEDI filings for HUGE within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Jan 04, 2022 03:30 ET
FSD Pharma to Present at the H.C. Wainwright Bioconnect Conference on January 10-13th
FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced today that Anthony Durkacz, Interim CEO of FSD Pharma, will present at the H.C. Wainwright Bioconnect Conference to be held virtually on January 10-13, 2022. Mr. Durkacz’s presentation will be available on-demand for conference attendees starting at 7:00 a.m. ET on January 10, 2022. To register, please
Read full article
Dec 30, 2021 03:30 ET
FSD Pharma Announces Share Repurchase Program
FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced today that its Board of Directors has authorized the repurchase by the Company of up to 2,000,000 of its Subordinate Class B Voting Shares (the “Subordinate Voting Shares”) from time to time over the next 12 months at prevailing market prices in order to allow the Company to use its excess cash reserves to strategically return value to shareholders.
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
1.03
--
--
Price to Sales - TTM
--
7.67
10.69
Price to Book - most recent quarter
0.69
1.76
2.52
Price to Cash Flow per share - TTM
--
11.26
13.73
Price to Free Cash Flow per share - TTM
--
28.63
28.71
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Dec 31, 2021181,028144,915
Dec 15, 202136,113-41,568
Nov 30, 202177,68137,718
See Short Report

Business Summary

Sector:  Healthcare Industry:  Pharmaceuticals

FSD Pharma Inc. is a Canada-based life science holding company focused on building a portfolio of assets and biotech solutions. The Company, through its subsidiary, FSD Biosciences Inc., is focused on pharmaceutical research and development (R&D) of its lead compound, FSD 201, ultra-micronized Palmitoyl (PEA). FSD 201 stabilizes mast cells of the human body and down-regulate the proinflammatory cytokines to effectuate an anti-inflammatory response. Lucid Psycheceuticals Inc., a subsidiary of the Company, has worldwide rights to compounds shown to prevent and reverse the biochemical mechanisms of progressive multiple sclerosis in multiple preclinical animal models. Additionally, the Company is focused on develop a psychoactive (psychedelic-based) therapeutic of neurodegenerative disorders.

See business summary

 

Twitter

Search (past week) for $HUGE.CA

  • No tweets found